Proteosome-hydrophobic 'foot' malaria peptide vaccines for Plasmodium falciparum and P. vivax.
The immunogenicity of synthetic peptides representing the repeating portions of circumsporozoite proteins of Plasmodium sporozoites was greatly increased by complexing them to proteosomes via hydrophobic moieties added to their amino termini. Proteosomes have been used safely in people in the development of meningococcal vaccines and therefore proteosome-peptide vaccines are prime candidates for use against malaria.
Lowell
G H
GH
Department of Bacterial Diseases, Walter Reed Army Institute of Research, Washington, DC 20307-5100.
Ballou
W R
WR
Smith
L F
LF
Zollinger
W D
WD
Hockmeyer
W T
WT
D000276:Adjuvants, Immunologic; D000818:Animals; D000913:Antibodies, Protozoan / Q000096:biosynthesis; D000953:Antigens, Protozoan / Q000276:immunology*; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology; D006801:Humans; D046911:Macromolecular Substances; D008288:Malaria / Q000517:prevention & control*; D009842:Oligopeptides / Q000276:immunology; D010963:Plasmodium falciparum / Q000276:immunology; D010966:Plasmodium vivax / Q000276:immunology; D015800:Protozoan Proteins; D014612:Vaccines / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000276:immunology*
D000276:Adjuvants, Immunologic; D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D001425:Bacterial Outer Membrane Proteins; D046911:Macromolecular Substances; D009842:Oligopeptides; D015800:Protozoan Proteins; D014612:Vaccines; D014614:Vaccines, Synthetic; C041595:circumsporozoite protein, Protozoan